Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 15Fallopian Tube Neoplasms 13Lung Neoplasms 11Melanoma 8Colorectal Neoplasms 8Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Brain Neoplasms 4Rectal Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Uveal Melanoma 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Oligodendroglioma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, B-Cell 2Lymphoma 2

Interventions

Temozolomide 5Radiotherapy 2Bevacizumab 2tozuleristide 1olutasidenib 1abemaciclib 1Radiation 1Nivolumab 1Megestrol Acetate 1Lomustine 1Lapatinib 1Irinotecan 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Disulfides 1Cyproheptadine 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinal Cord Neoplasms × Disulfides × Clear all
NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

National Cancer Institute (NCI)

Phase 2 Completed
97 enrolled 35 charts
CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡